Deferred income (Tables)

12 Months Ended

Dec. 31, 2022

Deferred income

Schedule of movement in the non-current and current deferred income

		Total		Gilead collaboration agreement for filgotinib		Gilead collaboration agreement for drug discovery platform (1)		Deferred income related to contracts in our fee-for-service segment		Other deferred income
		(Euro, in thousands)
On December 31, 2019	€	3,000,646	€	780,261	€	2,220,013	€	362	€	10
Upfront received		160,000		160,000
Milestones received		90,192		90,192
Significant financing component (2)		16,278		16,278
Revenue recognition of upfront		(411,417)		(181,816)		(229,601)
Revenue recognition of milestones		(46,261)		(46,261)
Other movements		(305)						(362)		57
On December 31, 2020		2,809,133		818,654		1,990,412		—		67
Upfront received		12,643		12,643
Significant financing component (2)		9,289		9,289
Revenue recognition of upfront		(433,884)		(203,301)		(230,582)
Revenue recognition of milestones		(32,408)		(32,408)
Other movements		(67)								(67)
On December 31, 2021		2,364,701		604,875		1,759,828		—		—
Milestones received		18,238		18,238
Significant financing component (2)		7,672		7,672
Revenue recognition of upfront		(370,078)		(139,655)		(230,423)
Revenue recognition of milestones		(34,777)		(34,777)
Other movements		3,474								3,474
On December 31, 2022	€	1,989,230	€	456,352	€	1,529,405	€	—	€	3,474

(1) The upfront received and the outstanding balance on December 31, 2022 and December 31, 2021 comprise the issuance liabilities for the warrants and the upfront payment allocated to the drug discovery platform.

(2) With regard to the additional consideration received for the extended cost sharing for filgotinib, we assume the existence of a sigificant financing component reflecting the time value of money on the estimated recognition period